Free Online Seminar: Practical Applications from Biomarker Discovery to Clinical Use

Multiplex Approach to Multifactorial Diseases: A New Era in Neurodegenerative Biomarker Research

Olink's neurobiomarker analysis is a proteomics method that allows for the highly sensitive and specific simultaneous measurement of neurodegenerative disease-related proteins from limited samples such as plasma, serum, and cerebrospinal fluid, using Proximity Extension Assay (PEA) technology. Olink Target 48 Neurodegeneration enables the absolute quantification of markers important in neurodegenerative disease research, such as Aß40, Aß42, pTau217, NfL, and GFAP, making it useful for longitudinal studies and inter-facility comparisons. Furthermore, by using Olink Explore HT and Target 96 Neurology, a broad protein profiling analysis including neuroinflammation and synaptic function becomes possible, supporting the identification of novel biomarkers and elucidation of pathological mechanisms. **Effects of Implementation** - Promotion of understanding disease mechanisms through comprehensive analysis of neuroinflammation-related proteins. - Increased efficiency in biomarker discovery and contribution to drug development research. - Ability to measure numerous proteins from a small amount of sample, allowing for effective use of valuable samples.

• Other protein analysis
• Research Antibodies
• Other Protein Research

Analysis platform adopted by the world's largest human proteome study, "UK Biobank-PPP."

Olink Explore HT is a next-generation multiplex proteomics analysis platform that extracts an overwhelming amount of information from small sample volumes. It can simultaneously measure over 5,400 proteins from just 2 µL of diverse samples such as plasma, serum, and CSF, achieving 99.5% high specificity and reproducibility through its unique PEA (Proximity Extension Assay) technology. By combining an automated workflow with NGS readouts, it enables high-precision and efficient analysis, accommodating a wide range of research phases from biomarker discovery to clinical research and drug development. Furthermore, it has been adopted in The UK Biobank Pharma Proteomics Project, the largest human proteome study in the world, demonstrating its performance and reliability in large-scale research projects. In addition to the installation of the equipment in laboratories, it is also available through service providers and Olink analysis services, with our staff supporting the experimental design phase according to research objectives and analysis needs.

• Other protein analysis
• Research Antibodies
• Other Protein Research

Research on neurodegenerative diseases using PEA technology, pioneering with the latest markers and absolute quantification.

Olink Target 48 Neurodegeneration is a high-performance proteomics panel specialized in neurodegenerative disease research. It can simultaneously measure 41 types of proteins, including the latest and important central nervous system biomarkers such as Aß40, Aß42, pTau217, NfL, and GFAP, which are gaining attention in Alzheimer's and Parkinson's disease research. This panel enables the acquisition of absolute quantification (ng/mL) data, which is difficult with other technologies, allowing for data comparison between studies and institutions, as well as high reproducibility in long-term longitudinal studies. With just 1µL of plasma or cerebrospinal fluid, high-sensitivity measurements can be achieved, maximizing the use of valuable clinical samples. Furthermore, by combining analyses with Olink's cytokine panel, it comprehensively captures neurodegeneration and neuroinflammation, significantly enhancing analytical power. The standardized workflow using the Signature Q100 system contributes broadly from basic research to clinical and drug discovery research.

• Analysis and sequencing services
• Other protein analysis
• Research Antibodies

On Tuesday, April 21, at Iidabashi, paperlogic will have a booth at "Canon Selection 2026." The theme of this event is "Paper Output × Data Utilization." It is a comprehensive exhibition filled with hints to promote DX in the office and achieve operational efficiency. At the venue, there will be the latest "Security Measures Seminar" to protect companies from supply chain attacks, as well as programs like creating promotional flyers that anyone can make, "Super Easy! PDF Utilization Techniques" to alleviate daily frustrations, and "Paperless Fax Experience" to support remote work, all aimed at solving on-site challenges. From paperlogic, we will introduce the 【paperlogic Electronic Contract】 as a solution for "Document Management and Back Office Digitization." We will have actual operation demonstrations at our booth and will directly address your concerns regarding document management. We also have special plans exclusively for Otsuka Corporation, so please come and visit us.

We will be holding a technical training session for MilkoScanFT3 as detailed below. In this training, we will provide a broad range of information useful for operating the equipment, including explanations of the principles and structure of the device, how to create measurement products, daily maintenance, and responses to troubleshooting. Additionally, this year we will introduce new ways to utilize digital services (such as FossCalibrator and IQX), and we have also prepared hands-on sessions where customers can experience operating the equipment using a PC. The training content is designed to be more practical and immediately applicable in real-world settings. We understand you may be busy, but we kindly ask you to consider participating. ■ Osaka Venue: June 25-26 ■ Morioka Venue: July 8-9 ■ Tokyo Venue: August 27-28 ■ Obihiro Venue: September 17-18 ■ Fukuoka Venue: October 8-9 *Please check the PDF for more details.

■Connecting Biomarker Discovery to Clinical Application - Explained with Real Cases of Neurodegenerative Diseases Although biomarkers are discovered, many do not reach clinical application. The reasons for this lie in multiple hurdles that arise after discovery, such as "narrowing down candidates," "reproducibility," and "connecting to clinical practice." 1. How should promising candidates obtained from comprehensive exploration be narrowed down? 2. How can reproducibility and scalability be ensured? 3. What are the key points for smoothly transitioning to clinical research? 4. What should be considered in data science throughout the overall flow? In this online seminar, we will clearly explain specific strategies for advancing from discovery to clinical application based on actual research cases of Alzheimer's disease and multiple sclerosis, in an easy-to-understand manner in Japanese. *Olink products and services are for research purposes only. Please note that they cannot be used for diagnostic purposes.

We would like to extend our heartfelt congratulations on the continued prosperity of your esteemed company. Our company will be exhibiting at the following trade show, where we will showcase a variety of products, including new ones. We sincerely invite you to visit us during this busy time. 【 Exhibition Name 】 Automotive Technology Exhibition 2025 YOKOHAMA https://aee.expo-info.jsae.or.jp/ja/yokohama/ (An "online exhibition" will also be held during and around the event period) 【 Dates 】 May 21 (Wednesday) - 23 (Friday), 2024 10:00 AM - 6:00 PM *On the final day, 9:00 AM - 4:00 PM (Online exhibition: May 14 (Wednesday) - June 4 (Wednesday)) 【 Venue 】 Pacifico Yokohama (1-1-1 Minatomirai, Nishi-ku, Yokohama, Kanagawa Prefecture) Our booth number: "Concourse 505"

We would like to extend our heartfelt congratulations on the continued prosperity of your esteemed company. Our company will be exhibiting at the following trade show, where we will showcase a variety of products, including new ones. We sincerely apologize for the inconvenience during your busy schedule, but we would like to invite you to attend this event. 【 Exhibition Name 】 27th INTERPHEX Week Tokyo https://www.interphex.jp/tokyo/ja-jp.html 【 Dates 】 July 9 (Wednesday) - 11 (Friday), 2025 10:00 AM - 5:00 PM 【 Venue 】 Tokyo Big Sight (3-11-1 Ariake, Koto-ku, Tokyo 135-0063)